About Chugai
Chugai’s mission is
to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Sep 25, 2024 Galderma’s Announcement Regarding Nemolizumab (Data Presentation at European Academy of Dermatology and Venereology)
- Sep 24, 2024 Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Refractory Steroid-Resistant Nephrotic Syndrome
- Sep 24, 2024 Chugai Receives Approvals for Additional Indication of Evrysdi in Pre-Symptomatic Spinal Muscular Atrophy (SMA) and Additional Dosage for SMA Infants Under 2 Months of Age
- Sep 09, 2024 Personnel Change
- Sep 06, 2024 Chugai Files in Japan for Additional Indication of Vabysmo for Angioid Streaks, a Leading Cause of Vision Loss
